Parsaclisib
 | |
| Clinical data | |
|---|---|
| ATC code | |
| Identifiers | |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C20H22ClFN6O2 |
| Molar mass | 432.88 g·mol−1 |
| 3D model (JSmol) | |
Parsaclisib is an investigational drug that it being evaluated for the treatment of B-cell malignancies. It is a PI3Kδ (phosphoinositide 3-kinase) inhibitor.[1][2]
References
[edit]- ^ Gerds AT, Bartalucci N, Assad A, Yacoub A (August 2022). "Targeting the PI3K pathway in myeloproliferative neoplasms". Expert Review of Anticancer Therapy. 22 (8): 835–843. doi:10.1080/14737140.2022.2093192. hdl:2158/1351132. PMID 35763287.
- ^ "Parsaclisib - Incyte Corporation". AdisInsight. Springer Nature Switzerland AG.
 | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |